Strategies for In Vivo Screening and Mitigation of Hepatotoxicity Associated with Antisense Drugs Article Swipe
Piotr J. Kamola
,
Klio Maratou
,
Paul A. Wilson
,
Kay Rush
,
T. Mullaney
,
Tom P. McKevitt
,
Paula Evans
,
Jim Ridings
,
Probash Chowdhury
,
Aude Roulois
,
Ann Fairchild
,
Sean J. McCawley
,
Karen Cartwright
,
Nigel J. Gooderham
,
Timothy W. Gant
,
Kitty Moores
,
Stephen Hughes
,
Mark R. Edbrooke
,
Kenneth L. Clark
,
Joel D. Parry
·
YOU?
·
· 2017
· Open Access
·
· DOI: https://doi.org/10.1016/j.omtn.2017.07.003
YOU?
·
· 2017
· Open Access
·
· DOI: https://doi.org/10.1016/j.omtn.2017.07.003
Related Topics
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1016/j.omtn.2017.07.003
- http://www.cell.com/article/S2162253117302135/pdf
- OA Status
- gold
- Cited By
- 57
- References
- 32
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W2730536591
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W2730536591Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1016/j.omtn.2017.07.003Digital Object Identifier
- Title
-
Strategies for In Vivo Screening and Mitigation of Hepatotoxicity Associated with Antisense DrugsWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2017Year of publication
- Publication date
-
2017-07-08Full publication date if available
- Authors
-
Piotr J. Kamola, Klio Maratou, Paul A. Wilson, Kay Rush, T. Mullaney, Tom P. McKevitt, Paula Evans, Jim Ridings, Probash Chowdhury, Aude Roulois, Ann Fairchild, Sean J. McCawley, Karen Cartwright, Nigel J. Gooderham, Timothy W. Gant, Kitty Moores, Stephen Hughes, Mark R. Edbrooke, Kenneth L. Clark, Joel D. ParryList of authors in order
- Landing page
-
https://doi.org/10.1016/j.omtn.2017.07.003Publisher landing page
- PDF URL
-
https://www.cell.com/article/S2162253117302135/pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.cell.com/article/S2162253117302135/pdfDirect OA link when available
- Concepts
-
In vivo, Pharmacology, Computational biology, Medicine, Chemistry, Biology, BiotechnologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
57Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 6, 2024: 15, 2023: 7, 2022: 10, 2020: 5Per-year citation counts (last 5 years)
- References (count)
-
32Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W2730536591 |
|---|---|
| doi | https://doi.org/10.1016/j.omtn.2017.07.003 |
| ids.doi | https://doi.org/10.1016/j.omtn.2017.07.003 |
| ids.mag | 2730536591 |
| ids.openalex | https://openalex.org/W2730536591 |
| fwci | 5.91853351 |
| type | article |
| title | Strategies for In Vivo Screening and Mitigation of Hepatotoxicity Associated with Antisense Drugs |
| biblio.issue | |
| biblio.volume | 8 |
| biblio.last_page | 394 |
| biblio.first_page | 383 |
| topics[0].id | https://openalex.org/T10211 |
| topics[0].field.id | https://openalex.org/fields/17 |
| topics[0].field.display_name | Computer Science |
| topics[0].score | 0.9854000210762024 |
| topics[0].domain.id | https://openalex.org/domains/3 |
| topics[0].domain.display_name | Physical Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/1703 |
| topics[0].subfield.display_name | Computational Theory and Mathematics |
| topics[0].display_name | Computational Drug Discovery Methods |
| topics[1].id | https://openalex.org/T11663 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.9800999760627747 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1312 |
| topics[1].subfield.display_name | Molecular Biology |
| topics[1].display_name | Viral Infectious Diseases and Gene Expression in Insects |
| topics[2].id | https://openalex.org/T10613 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.9689000248908997 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1311 |
| topics[2].subfield.display_name | Genetics |
| topics[2].display_name | Virus-based gene therapy research |
| funders[0].id | https://openalex.org/F4320307773 |
| funders[0].ror | https://ror.org/01xsqw823 |
| funders[0].display_name | GlaxoSmithKline |
| is_xpac | False |
| apc_list.value | 3900 |
| apc_list.currency | USD |
| apc_list.value_usd | 3900 |
| apc_paid.value | 3900 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 3900 |
| concepts[0].id | https://openalex.org/C207001950 |
| concepts[0].level | 2 |
| concepts[0].score | 0.6970398426055908 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q141124 |
| concepts[0].display_name | In vivo |
| concepts[1].id | https://openalex.org/C98274493 |
| concepts[1].level | 1 |
| concepts[1].score | 0.516349196434021 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[1].display_name | Pharmacology |
| concepts[2].id | https://openalex.org/C70721500 |
| concepts[2].level | 1 |
| concepts[2].score | 0.39267975091934204 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q177005 |
| concepts[2].display_name | Computational biology |
| concepts[3].id | https://openalex.org/C71924100 |
| concepts[3].level | 0 |
| concepts[3].score | 0.3691955804824829 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[3].display_name | Medicine |
| concepts[4].id | https://openalex.org/C185592680 |
| concepts[4].level | 0 |
| concepts[4].score | 0.33659571409225464 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[4].display_name | Chemistry |
| concepts[5].id | https://openalex.org/C86803240 |
| concepts[5].level | 0 |
| concepts[5].score | 0.28995251655578613 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[5].display_name | Biology |
| concepts[6].id | https://openalex.org/C150903083 |
| concepts[6].level | 1 |
| concepts[6].score | 0.1774255335330963 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q7108 |
| concepts[6].display_name | Biotechnology |
| keywords[0].id | https://openalex.org/keywords/in-vivo |
| keywords[0].score | 0.6970398426055908 |
| keywords[0].display_name | In vivo |
| keywords[1].id | https://openalex.org/keywords/pharmacology |
| keywords[1].score | 0.516349196434021 |
| keywords[1].display_name | Pharmacology |
| keywords[2].id | https://openalex.org/keywords/computational-biology |
| keywords[2].score | 0.39267975091934204 |
| keywords[2].display_name | Computational biology |
| keywords[3].id | https://openalex.org/keywords/medicine |
| keywords[3].score | 0.3691955804824829 |
| keywords[3].display_name | Medicine |
| keywords[4].id | https://openalex.org/keywords/chemistry |
| keywords[4].score | 0.33659571409225464 |
| keywords[4].display_name | Chemistry |
| keywords[5].id | https://openalex.org/keywords/biology |
| keywords[5].score | 0.28995251655578613 |
| keywords[5].display_name | Biology |
| keywords[6].id | https://openalex.org/keywords/biotechnology |
| keywords[6].score | 0.1774255335330963 |
| keywords[6].display_name | Biotechnology |
| language | en |
| locations[0].id | doi:10.1016/j.omtn.2017.07.003 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2764969478 |
| locations[0].source.issn | 2162-2531 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2162-2531 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Molecular Therapy — Nucleic Acids |
| locations[0].source.host_organization | https://openalex.org/P4310315673 |
| locations[0].source.host_organization_name | Cell Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310315673, https://openalex.org/P4310320990 |
| locations[0].source.host_organization_lineage_names | Cell Press, Elsevier BV |
| locations[0].license | cc-by-nc-nd |
| locations[0].pdf_url | http://www.cell.com/article/S2162253117302135/pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc-nd |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Molecular Therapy - Nucleic Acids |
| locations[0].landing_page_url | https://doi.org/10.1016/j.omtn.2017.07.003 |
| locations[1].id | pmh:oai:doaj.org/article:b04a0634ef634c9784c5c5759a036d27 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306401280 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[1].source.host_organization | |
| locations[1].source.host_organization_name | |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | article |
| locations[1].license_id | |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | Molecular Therapy: Nucleic Acids, Vol 8, Iss , Pp 383-394 (2017) |
| locations[1].landing_page_url | https://doaj.org/article/b04a0634ef634c9784c5c5759a036d27 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:5537172 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | |
| locations[2].landing_page_url | http://doi.org/10.1016/j.omtn.2017.07.003 |
| locations[3].id | pmh:oai:spiral.imperial.ac.uk:10044/1/50686 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S4306401396 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | Spiral (Imperial College London) |
| locations[3].source.host_organization | https://openalex.org/I47508984 |
| locations[3].source.host_organization_name | Imperial College London |
| locations[3].source.host_organization_lineage | https://openalex.org/I47508984 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Journal Article |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | 394 |
| locations[3].landing_page_url | http://hdl.handle.net/10044/1/50686 |
| indexed_in | crossref, doaj |
| authorships[0].author.id | https://openalex.org/A5026067835 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-7870-605X |
| authorships[0].author.display_name | Piotr J. Kamola |
| authorships[0].countries | GB |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I188950975 |
| authorships[0].affiliations[0].raw_affiliation_string | GlaxoSmithKline R&D, Stevenage SG1 2NY, UK |
| authorships[0].affiliations[1].institution_ids | https://openalex.org/I348769827 |
| authorships[0].affiliations[1].raw_affiliation_string | Centre for Radiation, Chemical and Environmental Hazards, Public Health England, Harwell Science and Innovation Campus, Oxfordshire OX11 0RQ, UK |
| authorships[0].affiliations[2].institution_ids | https://openalex.org/I47508984 |
| authorships[0].affiliations[2].raw_affiliation_string | Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK |
| authorships[0].affiliations[3].institution_ids | https://openalex.org/I188950975 |
| authorships[0].affiliations[3].raw_affiliation_string | GlaxoSmithKline R&D, Ware SG12 0DP, UK |
| authorships[0].institutions[0].id | https://openalex.org/I188950975 |
| authorships[0].institutions[0].ror | https://ror.org/01xsqw823 |
| authorships[0].institutions[0].type | company |
| authorships[0].institutions[0].lineage | https://openalex.org/I188950975 |
| authorships[0].institutions[0].country_code | GB |
| authorships[0].institutions[0].display_name | GlaxoSmithKline (United Kingdom) |
| authorships[0].institutions[1].id | https://openalex.org/I47508984 |
| authorships[0].institutions[1].ror | https://ror.org/041kmwe10 |
| authorships[0].institutions[1].type | education |
| authorships[0].institutions[1].lineage | https://openalex.org/I47508984 |
| authorships[0].institutions[1].country_code | GB |
| authorships[0].institutions[1].display_name | Imperial College London |
| authorships[0].institutions[2].id | https://openalex.org/I348769827 |
| authorships[0].institutions[2].ror | https://ror.org/00vbvha87 |
| authorships[0].institutions[2].type | government |
| authorships[0].institutions[2].lineage | https://openalex.org/I1311074006, https://openalex.org/I348769827 |
| authorships[0].institutions[2].country_code | GB |
| authorships[0].institutions[2].display_name | Public Health England |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Piotr J. Kamola |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Centre for Radiation, Chemical and Environmental Hazards, Public Health England, Harwell Science and Innovation Campus, Oxfordshire OX11 0RQ, UK, Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK, GlaxoSmithKline R&D, Stevenage SG1 2NY, UK, GlaxoSmithKline R&D, Ware SG12 0DP, UK |
| authorships[1].author.id | https://openalex.org/A5057517083 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-6061-2322 |
| authorships[1].author.display_name | Klio Maratou |
| authorships[1].countries | GB |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I188950975 |
| authorships[1].affiliations[0].raw_affiliation_string | GlaxoSmithKline R&D, Stevenage SG1 2NY, UK |
| authorships[1].institutions[0].id | https://openalex.org/I188950975 |
| authorships[1].institutions[0].ror | https://ror.org/01xsqw823 |
| authorships[1].institutions[0].type | company |
| authorships[1].institutions[0].lineage | https://openalex.org/I188950975 |
| authorships[1].institutions[0].country_code | GB |
| authorships[1].institutions[0].display_name | GlaxoSmithKline (United Kingdom) |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Klio Maratou |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | GlaxoSmithKline R&D, Stevenage SG1 2NY, UK |
| authorships[2].author.id | https://openalex.org/A5033735039 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-4151-1846 |
| authorships[2].author.display_name | Paul A. Wilson |
| authorships[2].countries | GB |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I188950975 |
| authorships[2].affiliations[0].raw_affiliation_string | GlaxoSmithKline R&D, Stevenage SG1 2NY, UK |
| authorships[2].institutions[0].id | https://openalex.org/I188950975 |
| authorships[2].institutions[0].ror | https://ror.org/01xsqw823 |
| authorships[2].institutions[0].type | company |
| authorships[2].institutions[0].lineage | https://openalex.org/I188950975 |
| authorships[2].institutions[0].country_code | GB |
| authorships[2].institutions[0].display_name | GlaxoSmithKline (United Kingdom) |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Paul A. Wilson |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | GlaxoSmithKline R&D, Stevenage SG1 2NY, UK |
| authorships[3].author.id | https://openalex.org/A5027122502 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Kay Rush |
| authorships[3].countries | GB |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I188950975 |
| authorships[3].affiliations[0].raw_affiliation_string | GlaxoSmithKline R&D, Ware SG12 0DP, UK |
| authorships[3].institutions[0].id | https://openalex.org/I188950975 |
| authorships[3].institutions[0].ror | https://ror.org/01xsqw823 |
| authorships[3].institutions[0].type | company |
| authorships[3].institutions[0].lineage | https://openalex.org/I188950975 |
| authorships[3].institutions[0].country_code | GB |
| authorships[3].institutions[0].display_name | GlaxoSmithKline (United Kingdom) |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Kay Rush |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | GlaxoSmithKline R&D, Ware SG12 0DP, UK |
| authorships[4].author.id | https://openalex.org/A5033809172 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | T. Mullaney |
| authorships[4].countries | GB |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I188950975 |
| authorships[4].affiliations[0].raw_affiliation_string | GlaxoSmithKline R&D, Ware SG12 0DP, UK |
| authorships[4].institutions[0].id | https://openalex.org/I188950975 |
| authorships[4].institutions[0].ror | https://ror.org/01xsqw823 |
| authorships[4].institutions[0].type | company |
| authorships[4].institutions[0].lineage | https://openalex.org/I188950975 |
| authorships[4].institutions[0].country_code | GB |
| authorships[4].institutions[0].display_name | GlaxoSmithKline (United Kingdom) |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Tanya Mullaney |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | GlaxoSmithKline R&D, Ware SG12 0DP, UK |
| authorships[5].author.id | https://openalex.org/A5062525015 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Tom P. McKevitt |
| authorships[5].countries | GB |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I188950975 |
| authorships[5].affiliations[0].raw_affiliation_string | GlaxoSmithKline R&D, Ware SG12 0DP, UK |
| authorships[5].institutions[0].id | https://openalex.org/I188950975 |
| authorships[5].institutions[0].ror | https://ror.org/01xsqw823 |
| authorships[5].institutions[0].type | company |
| authorships[5].institutions[0].lineage | https://openalex.org/I188950975 |
| authorships[5].institutions[0].country_code | GB |
| authorships[5].institutions[0].display_name | GlaxoSmithKline (United Kingdom) |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Tom McKevitt |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | GlaxoSmithKline R&D, Ware SG12 0DP, UK |
| authorships[6].author.id | https://openalex.org/A5083916049 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Paula Evans |
| authorships[6].countries | GB |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I188950975 |
| authorships[6].affiliations[0].raw_affiliation_string | GlaxoSmithKline R&D, Ware SG12 0DP, UK |
| authorships[6].institutions[0].id | https://openalex.org/I188950975 |
| authorships[6].institutions[0].ror | https://ror.org/01xsqw823 |
| authorships[6].institutions[0].type | company |
| authorships[6].institutions[0].lineage | https://openalex.org/I188950975 |
| authorships[6].institutions[0].country_code | GB |
| authorships[6].institutions[0].display_name | GlaxoSmithKline (United Kingdom) |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Paula Evans |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | GlaxoSmithKline R&D, Ware SG12 0DP, UK |
| authorships[7].author.id | https://openalex.org/A5034477304 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Jim Ridings |
| authorships[7].countries | GB |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I188950975 |
| authorships[7].affiliations[0].raw_affiliation_string | GlaxoSmithKline R&D, Ware SG12 0DP, UK |
| authorships[7].institutions[0].id | https://openalex.org/I188950975 |
| authorships[7].institutions[0].ror | https://ror.org/01xsqw823 |
| authorships[7].institutions[0].type | company |
| authorships[7].institutions[0].lineage | https://openalex.org/I188950975 |
| authorships[7].institutions[0].country_code | GB |
| authorships[7].institutions[0].display_name | GlaxoSmithKline (United Kingdom) |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Jim Ridings |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | GlaxoSmithKline R&D, Ware SG12 0DP, UK |
| authorships[8].author.id | https://openalex.org/A5028993838 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | Probash Chowdhury |
| authorships[8].countries | GB |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I188950975 |
| authorships[8].affiliations[0].raw_affiliation_string | GlaxoSmithKline R&D, Ware SG12 0DP, UK |
| authorships[8].institutions[0].id | https://openalex.org/I188950975 |
| authorships[8].institutions[0].ror | https://ror.org/01xsqw823 |
| authorships[8].institutions[0].type | company |
| authorships[8].institutions[0].lineage | https://openalex.org/I188950975 |
| authorships[8].institutions[0].country_code | GB |
| authorships[8].institutions[0].display_name | GlaxoSmithKline (United Kingdom) |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Probash Chowdhury |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | GlaxoSmithKline R&D, Ware SG12 0DP, UK |
| authorships[9].author.id | https://openalex.org/A5045679720 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | Aude Roulois |
| authorships[9].countries | GB |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I188950975 |
| authorships[9].affiliations[0].raw_affiliation_string | GlaxoSmithKline R&D, Ware SG12 0DP, UK |
| authorships[9].institutions[0].id | https://openalex.org/I188950975 |
| authorships[9].institutions[0].ror | https://ror.org/01xsqw823 |
| authorships[9].institutions[0].type | company |
| authorships[9].institutions[0].lineage | https://openalex.org/I188950975 |
| authorships[9].institutions[0].country_code | GB |
| authorships[9].institutions[0].display_name | GlaxoSmithKline (United Kingdom) |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Aude Roulois |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | GlaxoSmithKline R&D, Ware SG12 0DP, UK |
| authorships[10].author.id | https://openalex.org/A5052540477 |
| authorships[10].author.orcid | |
| authorships[10].author.display_name | Ann Fairchild |
| authorships[10].countries | GB |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I188950975 |
| authorships[10].affiliations[0].raw_affiliation_string | GlaxoSmithKline R&D, Ware SG12 0DP, UK |
| authorships[10].institutions[0].id | https://openalex.org/I188950975 |
| authorships[10].institutions[0].ror | https://ror.org/01xsqw823 |
| authorships[10].institutions[0].type | company |
| authorships[10].institutions[0].lineage | https://openalex.org/I188950975 |
| authorships[10].institutions[0].country_code | GB |
| authorships[10].institutions[0].display_name | GlaxoSmithKline (United Kingdom) |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Ann Fairchild |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | GlaxoSmithKline R&D, Ware SG12 0DP, UK |
| authorships[11].author.id | https://openalex.org/A5034716354 |
| authorships[11].author.orcid | |
| authorships[11].author.display_name | Sean J. McCawley |
| authorships[11].countries | GB |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I188950975 |
| authorships[11].affiliations[0].raw_affiliation_string | GlaxoSmithKline R&D, Ware SG12 0DP, UK |
| authorships[11].institutions[0].id | https://openalex.org/I188950975 |
| authorships[11].institutions[0].ror | https://ror.org/01xsqw823 |
| authorships[11].institutions[0].type | company |
| authorships[11].institutions[0].lineage | https://openalex.org/I188950975 |
| authorships[11].institutions[0].country_code | GB |
| authorships[11].institutions[0].display_name | GlaxoSmithKline (United Kingdom) |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Sean McCawley |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | GlaxoSmithKline R&D, Ware SG12 0DP, UK |
| authorships[12].author.id | https://openalex.org/A5078658017 |
| authorships[12].author.orcid | |
| authorships[12].author.display_name | Karen Cartwright |
| authorships[12].countries | GB |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I188950975 |
| authorships[12].affiliations[0].raw_affiliation_string | GlaxoSmithKline R&D, Ware SG12 0DP, UK |
| authorships[12].institutions[0].id | https://openalex.org/I188950975 |
| authorships[12].institutions[0].ror | https://ror.org/01xsqw823 |
| authorships[12].institutions[0].type | company |
| authorships[12].institutions[0].lineage | https://openalex.org/I188950975 |
| authorships[12].institutions[0].country_code | GB |
| authorships[12].institutions[0].display_name | GlaxoSmithKline (United Kingdom) |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Karen Cartwright |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | GlaxoSmithKline R&D, Ware SG12 0DP, UK |
| authorships[13].author.id | https://openalex.org/A5005346296 |
| authorships[13].author.orcid | https://orcid.org/0000-0001-7645-8219 |
| authorships[13].author.display_name | Nigel J. Gooderham |
| authorships[13].countries | GB |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I47508984 |
| authorships[13].affiliations[0].raw_affiliation_string | Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK |
| authorships[13].institutions[0].id | https://openalex.org/I47508984 |
| authorships[13].institutions[0].ror | https://ror.org/041kmwe10 |
| authorships[13].institutions[0].type | education |
| authorships[13].institutions[0].lineage | https://openalex.org/I47508984 |
| authorships[13].institutions[0].country_code | GB |
| authorships[13].institutions[0].display_name | Imperial College London |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Nigel J. Gooderham |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK |
| authorships[14].author.id | https://openalex.org/A5078090457 |
| authorships[14].author.orcid | https://orcid.org/0000-0001-9057-4937 |
| authorships[14].author.display_name | Timothy W. Gant |
| authorships[14].countries | GB |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I348769827 |
| authorships[14].affiliations[0].raw_affiliation_string | Centre for Radiation, Chemical and Environmental Hazards, Public Health England, Harwell Science and Innovation Campus, Oxfordshire OX11 0RQ, UK |
| authorships[14].institutions[0].id | https://openalex.org/I348769827 |
| authorships[14].institutions[0].ror | https://ror.org/00vbvha87 |
| authorships[14].institutions[0].type | government |
| authorships[14].institutions[0].lineage | https://openalex.org/I1311074006, https://openalex.org/I348769827 |
| authorships[14].institutions[0].country_code | GB |
| authorships[14].institutions[0].display_name | Public Health England |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Timothy W. Gant |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | Centre for Radiation, Chemical and Environmental Hazards, Public Health England, Harwell Science and Innovation Campus, Oxfordshire OX11 0RQ, UK |
| authorships[15].author.id | https://openalex.org/A5069287119 |
| authorships[15].author.orcid | |
| authorships[15].author.display_name | Kitty Moores |
| authorships[15].countries | GB |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I188950975 |
| authorships[15].affiliations[0].raw_affiliation_string | GlaxoSmithKline R&D, Stevenage SG1 2NY, UK |
| authorships[15].institutions[0].id | https://openalex.org/I188950975 |
| authorships[15].institutions[0].ror | https://ror.org/01xsqw823 |
| authorships[15].institutions[0].type | company |
| authorships[15].institutions[0].lineage | https://openalex.org/I188950975 |
| authorships[15].institutions[0].country_code | GB |
| authorships[15].institutions[0].display_name | GlaxoSmithKline (United Kingdom) |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Kitty Moores |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | GlaxoSmithKline R&D, Stevenage SG1 2NY, UK |
| authorships[16].author.id | https://openalex.org/A5075930262 |
| authorships[16].author.orcid | |
| authorships[16].author.display_name | Stephen Hughes |
| authorships[16].countries | GB |
| authorships[16].affiliations[0].institution_ids | https://openalex.org/I188950975 |
| authorships[16].affiliations[0].raw_affiliation_string | GlaxoSmithKline R&D, Stevenage SG1 2NY, UK |
| authorships[16].institutions[0].id | https://openalex.org/I188950975 |
| authorships[16].institutions[0].ror | https://ror.org/01xsqw823 |
| authorships[16].institutions[0].type | company |
| authorships[16].institutions[0].lineage | https://openalex.org/I188950975 |
| authorships[16].institutions[0].country_code | GB |
| authorships[16].institutions[0].display_name | GlaxoSmithKline (United Kingdom) |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | Stephen A. Hughes |
| authorships[16].is_corresponding | False |
| authorships[16].raw_affiliation_strings | GlaxoSmithKline R&D, Stevenage SG1 2NY, UK |
| authorships[17].author.id | https://openalex.org/A5002246418 |
| authorships[17].author.orcid | |
| authorships[17].author.display_name | Mark R. Edbrooke |
| authorships[17].countries | GB |
| authorships[17].affiliations[0].institution_ids | https://openalex.org/I188950975 |
| authorships[17].affiliations[0].raw_affiliation_string | GlaxoSmithKline R&D, Stevenage SG1 2NY, UK |
| authorships[17].institutions[0].id | https://openalex.org/I188950975 |
| authorships[17].institutions[0].ror | https://ror.org/01xsqw823 |
| authorships[17].institutions[0].type | company |
| authorships[17].institutions[0].lineage | https://openalex.org/I188950975 |
| authorships[17].institutions[0].country_code | GB |
| authorships[17].institutions[0].display_name | GlaxoSmithKline (United Kingdom) |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | Mark R. Edbrooke |
| authorships[17].is_corresponding | False |
| authorships[17].raw_affiliation_strings | GlaxoSmithKline R&D, Stevenage SG1 2NY, UK |
| authorships[18].author.id | https://openalex.org/A5031865992 |
| authorships[18].author.orcid | https://orcid.org/0000-0003-0534-9677 |
| authorships[18].author.display_name | Kenneth L. Clark |
| authorships[18].countries | GB |
| authorships[18].affiliations[0].institution_ids | https://openalex.org/I188950975 |
| authorships[18].affiliations[0].raw_affiliation_string | GlaxoSmithKline R&D, Stevenage SG1 2NY, UK |
| authorships[18].institutions[0].id | https://openalex.org/I188950975 |
| authorships[18].institutions[0].ror | https://ror.org/01xsqw823 |
| authorships[18].institutions[0].type | company |
| authorships[18].institutions[0].lineage | https://openalex.org/I188950975 |
| authorships[18].institutions[0].country_code | GB |
| authorships[18].institutions[0].display_name | GlaxoSmithKline (United Kingdom) |
| authorships[18].author_position | middle |
| authorships[18].raw_author_name | Kenneth Clark |
| authorships[18].is_corresponding | False |
| authorships[18].raw_affiliation_strings | GlaxoSmithKline R&D, Stevenage SG1 2NY, UK |
| authorships[19].author.id | https://openalex.org/A5022140456 |
| authorships[19].author.orcid | |
| authorships[19].author.display_name | Joel D. Parry |
| authorships[19].countries | GB |
| authorships[19].affiliations[0].institution_ids | https://openalex.org/I188950975 |
| authorships[19].affiliations[0].raw_affiliation_string | GlaxoSmithKline R&D, Ware SG12 0DP, UK |
| authorships[19].institutions[0].id | https://openalex.org/I188950975 |
| authorships[19].institutions[0].ror | https://ror.org/01xsqw823 |
| authorships[19].institutions[0].type | company |
| authorships[19].institutions[0].lineage | https://openalex.org/I188950975 |
| authorships[19].institutions[0].country_code | GB |
| authorships[19].institutions[0].display_name | GlaxoSmithKline (United Kingdom) |
| authorships[19].author_position | last |
| authorships[19].raw_author_name | Joel D. Parry |
| authorships[19].is_corresponding | False |
| authorships[19].raw_affiliation_strings | GlaxoSmithKline R&D, Ware SG12 0DP, UK |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | http://www.cell.com/article/S2162253117302135/pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Strategies for In Vivo Screening and Mitigation of Hepatotoxicity Associated with Antisense Drugs |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10211 |
| primary_topic.field.id | https://openalex.org/fields/17 |
| primary_topic.field.display_name | Computer Science |
| primary_topic.score | 0.9854000210762024 |
| primary_topic.domain.id | https://openalex.org/domains/3 |
| primary_topic.domain.display_name | Physical Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/1703 |
| primary_topic.subfield.display_name | Computational Theory and Mathematics |
| primary_topic.display_name | Computational Drug Discovery Methods |
| related_works | https://openalex.org/W4387497383, https://openalex.org/W2948807893, https://openalex.org/W2899084033, https://openalex.org/W2778153218, https://openalex.org/W2748952813, https://openalex.org/W1531601525, https://openalex.org/W4391375266, https://openalex.org/W3031052312, https://openalex.org/W4389568370, https://openalex.org/W3032375762 |
| cited_by_count | 57 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 6 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 15 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 7 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 10 |
| counts_by_year[4].year | 2020 |
| counts_by_year[4].cited_by_count | 5 |
| counts_by_year[5].year | 2019 |
| counts_by_year[5].cited_by_count | 6 |
| counts_by_year[6].year | 2018 |
| counts_by_year[6].cited_by_count | 7 |
| counts_by_year[7].year | 2017 |
| counts_by_year[7].cited_by_count | 1 |
| locations_count | 4 |
| best_oa_location.id | doi:10.1016/j.omtn.2017.07.003 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2764969478 |
| best_oa_location.source.issn | 2162-2531 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2162-2531 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Molecular Therapy — Nucleic Acids |
| best_oa_location.source.host_organization | https://openalex.org/P4310315673 |
| best_oa_location.source.host_organization_name | Cell Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310315673, https://openalex.org/P4310320990 |
| best_oa_location.source.host_organization_lineage_names | Cell Press, Elsevier BV |
| best_oa_location.license | cc-by-nc-nd |
| best_oa_location.pdf_url | http://www.cell.com/article/S2162253117302135/pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Molecular Therapy - Nucleic Acids |
| best_oa_location.landing_page_url | https://doi.org/10.1016/j.omtn.2017.07.003 |
| primary_location.id | doi:10.1016/j.omtn.2017.07.003 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2764969478 |
| primary_location.source.issn | 2162-2531 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2162-2531 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Molecular Therapy — Nucleic Acids |
| primary_location.source.host_organization | https://openalex.org/P4310315673 |
| primary_location.source.host_organization_name | Cell Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310315673, https://openalex.org/P4310320990 |
| primary_location.source.host_organization_lineage_names | Cell Press, Elsevier BV |
| primary_location.license | cc-by-nc-nd |
| primary_location.pdf_url | http://www.cell.com/article/S2162253117302135/pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Molecular Therapy - Nucleic Acids |
| primary_location.landing_page_url | https://doi.org/10.1016/j.omtn.2017.07.003 |
| publication_date | 2017-07-08 |
| publication_year | 2017 |
| referenced_works | https://openalex.org/W2118601234, https://openalex.org/W2162510215, https://openalex.org/W2146350588, https://openalex.org/W2109137574, https://openalex.org/W2114775015, https://openalex.org/W2030120319, https://openalex.org/W2004232523, https://openalex.org/W2088707712, https://openalex.org/W2092474773, https://openalex.org/W1908974948, https://openalex.org/W2318775098, https://openalex.org/W2190875401, https://openalex.org/W6822274436, https://openalex.org/W1502920935, https://openalex.org/W6722148404, https://openalex.org/W2040089348, https://openalex.org/W2479276668, https://openalex.org/W6689918956, https://openalex.org/W2482598541, https://openalex.org/W1870321215, https://openalex.org/W1602607863, https://openalex.org/W1708837772, https://openalex.org/W2121836743, https://openalex.org/W2169456326, https://openalex.org/W2138207763, https://openalex.org/W2096465161, https://openalex.org/W2179438025, https://openalex.org/W1600624961, https://openalex.org/W1528297898, https://openalex.org/W2485758932, https://openalex.org/W2030293262, https://openalex.org/W2239874339 |
| referenced_works_count | 32 |
| abstract_inverted_index | |
| cited_by_percentile_year.max | 99 |
| cited_by_percentile_year.min | 90 |
| corresponding_author_ids | https://openalex.org/A5026067835 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 20 |
| corresponding_institution_ids | https://openalex.org/I188950975, https://openalex.org/I348769827, https://openalex.org/I47508984 |
| citation_normalized_percentile.value | 0.95646232 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |